PP01.77 EMERGE 402: Real-world Characteristics and Safety of Lurbinectedin in Small-cell Lung Cancer (SCLC)

Authors

D. Schreeder, Clearview Cancer Institute, Huntsville, United States
F. Badin, Baptist Health Medical Group, Lexington, United States
S. Dakhil, Cancer Center of Kansas, Wichita, United States
P. Lammers, Baptist Cancer Center, Memphis, United States
Mehul Patel, Rochester Regional HealthFollow
D. Slater, Eastern Connecticut Hematology and Oncology Associates, Norwich, United States
J. Migas, Mid-Illinois Hematology and Oncology Associates, Ltd., Normal, United States
N. Naveh, Jazz Pharmaceuticals, Philadelphia, United States
A. Boccuti, Jazz Pharmaceuticals, Philadelphia, United States
R. Hanvesakul, Jazz Pharmaceuticals, Oxford, United Kingdom
W. Li, Jazz Pharmaceuticals, Philadelphia, United States
B. Halmos, Albert Einstein College of Medicine, Bronx, United States

Department

Oncology and Hematology

Document Type

Conference Proceeding

Publication Title

Journal of Thoracic Oncology

Conference Name

North American Conference on Lung Cancer

Conference Date

2022-09-23 - 2022-09-25

First Page

e43

DOI

10.1016/j.jtho.2022.09.103

Volume

18

Issue

3, Supplement

Publication Date

3-2023

Recommended Citation

Schreeder, D., Badin, F., Dakhil, S., Lammers, P., Patel, M., Slater, D., Migas, J., Naveh, N., Boccuti, A., Hanvesakul, R., Li, W., & Halmos, B. (2023). PP01.77 EMERGE 402: Real-world Characteristics and Safety of Lurbinectedin in Small-cell Lung Cancer (SCLC). Journal of Thoracic Oncology, 18 (3, Supplement), e43. https://doi.org/10.1016/j.jtho.2022.09.103